9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma

Estimated reading time: < 1 min

Condition: Mesothelioma, Malignant

Estimated Enrollment: 35

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Recruiting

Study Results: No Results Available

Outcome Measures: Response Rate,  Adverse event assessment,  Progression-free survival, Overall survival

Interventions: Nivolumab, Ramucirumab

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: June 2020

Completion Date: June 2021

Last  Posted Date: July 11, 2019

Location: Moffitt Cancer Center, Tampa, Florida, United States

Website Link: https://ClinicalTrials.gov/show/NCT03502746

Was this article helpful?
Dislike 0